Research progress of potassium sodium hydrogen citrate in the prevention and treatment of urinary calculi
-
摘要: 泌尿系结石是泌尿科较为常见的疾病之一,具有病因和结石成分复杂、复发率高等特点。枸橼酸氢钾钠颗粒是中国泌尿外科医生常用的结石防治药物之一,是常用的尿酸结石口服溶石治疗药物和非感染结石预防性治疗药物。本研究对近年来枸橼酸氢钾钠国内外基础与临床研究进展进行综述,以期为临床提供决策参考。Abstract: Urolithiasis is one of the most common diseases in Department of Urology, and it has the characteristics of complex etiology, complex stone composition and high recurrence rate. Potassium sodium hydrogen citrate granule is one of the frequently used drugs for stone prevention and treatment by urologists in China, and are commonly used in the treatment of uric acid calculi and prophylactic treatment of non-infectious stones. This study reviewed the basic and clinical researches of potassium sodium hydrogen citrate in recent years in order to provide references for clinical decision-making.
-
Keywords:
- urolithiasis /
- potassium sodium hydrogen citrate /
- uric acid stone /
- cystine stone /
- recurrence
-
-
SKOLARIKOS A, STRAUB M, KNOLL T, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines[J]. Eur Urol, 2015, 67(4): 750-763.
孙颖浩, 黄健. 中国泌尿外科和男科疾病诊断治疗指南[M]. 北京: 科学出版社, 2020: 38-45. TAGUCHI K, CHO S Y, NG A C, et al. The Urological Association of Asia clinical guideline for urinary stone disease[J]. Int J Urol, 2019, 26(7): 688-709.
TURK C, SKOLARIKOS A, NEISIUS A, et al. EAU guidelines on urolithiasis[M]. Netherlands: European Association of Urology Guidelines Office, 2020: 131-134.
MA Q, FANG L, SU R, et al. Uric acid stones, clinical manifestations and therapeutic considerations[J]. Postgrad Med J, 2018, 94(1114): 458-462.
崔苏萍, 朱遵伟, 习海波, 等. 尿酸结石的诊断及治疗(附16例报告)[J]. 实用临床医学, 2006, 7(7): 55-57. RINNAB L, HAUTMANN R E, STRAUB M. Alkalizitrate in der Urologie[J]. Urologe A, 2004, 43(4): 429-439.
HONDA M, YAMAMOTO K, MOMOHARA C, et al. Oral chemolysis of uric acid stones[J]. Hinyokika Kiyo, 2003, 49(6): 307-310.
NEVO A, LEVI O, SIDI A M, et al. Patients treated for uric acid stones reoccur more often and within a shorter interval in comparison to patients treated for calcium stones[J]. Can Urol Assoc J, 2019, 14(11): 1121-1126.
PETRITSCH P H. Uric acid calculi: results of conservative treatment[J]. Urology, 1977, 10(6): 536-538.
EL-GAMAL O, EL-BENDARY M, RAGAB M, et al. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi[J]. Urol Res, 2012, 40(3): 219-224.
SALEM S M, SULTAN M F, BADAWY A. Oral dissolution therapy for renal radiolucent stones, outcome, and factors affecting response: a prospective study[J]. Urol Ann, 2019, 11(4): 369-373.
ELDERWY A A, KURKAR A, HUSSEIN A, et al. Dissolution therapy versus shock wave lithotripsy for radiolucent renal stones in children: a prospective study[J]. J Urol, 2014, 191(Suppl 5): 1491-1495.
RODMAN J S, WILLIAMS J J, PETERSON C M. Dissolution of uric acid calculi[J]. J Urol, 1984, 131(6): 1039-1044.
GRANADOS LOARCA E A. Medical treatment of uric acid lithiasis of the urinary tract and usefulness of double J catheter[J]. Arch Esp Urol, 2001, 54(2): 157-161.
MOKHLESS I A, SAKR M A, ABDELDAEIM H M, et al. Radiolucent renal stones in children: combined use of shock wave lithotripsy and dissolution therapy[J]. Urology, 2009, 73(4): 772-775.
ELBASET M A, HASHEM A, ERAKY A, et al. Optimal non-invasive treatment of 1-2. 5 cm radiolucent renal stones: oral dissolution therapy, shock wave lithotripsy or combined treatment-a randomized controlled trial[J]. World J Urol, 2020, 38(1): 207-212.
KAMPHUIS G M, WOUTER VAN HATTUM J, DE BIE P, et al. Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review[J]. Transl Androl Urol, 2019, 8(Suppl 4): S448-S456.
CANALES B K, SHARMA N, YUZHAKOV S V, et al. Long-term recurrence rates in uric acid stone formers with or without medical management[J]. Urology, 2019, 131: 46-52.
PAK C Y, SAKHAEE K, FULLER C. Successful management of uric acid nephrolithiasis with potassium citrate[J]. Kidney Int, 1986, 30(3): 422-428.
SAKHAEE K, HARVEY J A, PADALINO P K, et al. The potential role of salt abuse on the risk for kidney stone formation[J]. J Urol, 1993, 150(2 Pt 1): 310-312.
COIFFIER B, ALTMAN A, PUI C H, et al. Guidelines for the management of pediatric and adult tumor Lysis syndrome: an evidence-based review[J]. J Clin Oncol, 2008, 26(16): 2767-2778.
KATO Y, YAMAGUCHI S, YACHIKU S, et al. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis[J]. Urology, 2004, 63(1): 7-11.
HAUSER W, FRICK J, KUNIT G. Alkali citrate for preventing recurrence of calcium oxalate stones[J]. Eur Urol, 1990, 17(3): 248-251.
CHAUDHARY A, SINGLA S K, TANDON C. In vitro evaluation of Terminalia arjuna on calcium phosphate and calcium oxalate crystallization[J]. Indian J Pharm Sci, 2010, 72(3): 340-345.
YE Z Q, ZENG G H, YANG H, et al. The status and characteristics of urinary stone composition in China[J]. BJU Int, 2020, 125(6): 801-809.
ABOU CHAKRA M, DELLIS A E, PAPATSORIS A G, et al. Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium[J]. Expert Opin Pharmacother, 2020, 21(1): 85-96.
RODGERS A, ALLIE-HAMDULAY S, JACKSON G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor[J]. Nephrol Dial Transplant, 2006, 21(2): 361-369.
DUAN C Y, XIA Z Y, ZHANG G N, et al. Changes in urinary nanocrystallites in calcium oxalate stone formers before and after potassium citrate intake[J]. Int J Nanomedicine, 2013, 8: 909-918.
ERWIN D T, KOK D J, ALAM J, et al. Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton[J]. Am J Kidney Dis, 1994, 24(6): 893-900.
CAUDARELLA R, VESCINI F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment[J]. Arch Ital Urol Androl, 2009, 81(3): 182-187.
SHENG X X, JUNG T, WESSON J A, et al. Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents[J]. Proc Natl Acad Sci USA, 2005, 102(2): 267-272.
李颢, 李康健, 罗钰辉, 等. 云南白族人群特发性低枸橼酸尿症与维生素D受体基因rs2228570和rs1544410单核苷酸多态性的关系[J]. 中华实验外科杂志, 2016, 33(5): 1397-1400. RENDINA D, DE FILIPPO G, GIANFRANCESCO F, et al. Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers[J]. J Nephrol, 2017, 30(3): 411-418.
PAK C Y. Citrate and renal calculi: an update[J]. Miner Electrolyte Metab, 1994, 20(6): 371-377.
代海涛, 陈志强, 叶章群. 枸橼酸氢钾钠降低草酸钙结石成石危险性的机制[J]. 临床泌尿外科杂志, 2007, 22(4): 287-288 , 291.
姚秀琼, 欧阳健明, 庞乃章. 泌尿系结石患者尿液中草酸钙结晶的研究[J]. 广东药学院学报, 2005, 21(1): 1-3. CICERELLO E, MERLO F, GAMBARO G, et al. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients[J]. J Urol, 1994, 151(1): 5-9.
孙西钊. 枸橼酸氢钾钠防治尿石症研究进展[J]. 中华实验外科杂志, 2005, 22(9): 1148-1149. PREMINGER G M. New developments in the management of urolithiasis[M]. New York: Igaku-Shoin Medical Publishers, 1998: 183-193.
黄辉, 田维云, 叶建国, 等. 枸橼酸氢钾钠延长双J管在体内留置时间的疗效观察[J]. 国际泌尿系统杂志, 2019, 39(3): 498-501. LOJANAPIWAT B, TANTHANUCH M, PRIPATHANONT C, et al. Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy[J]. Int Braz J Urol, 2011, 37(5): 611-616.
袁响林. 超声诊断肾结晶与肾功能的相关性研究[D]. 昆明: 昆明医科大学, 2019. CHEN Z. Potassium-sodium citrate prevents the development of renal microcalculi into symptomatic stones in calcium stone-forming patients[J]. Int J Urol, 2017, 24(4): 334-339.
黄辉, 王彤, 陈洁, 等. 枸橼酸氢钾钠溶解肾集合管结晶的临床观察[J]. 中国临床实用医学, 2008, 2(9): 1-2. SCHERER K, BRAIG E, WILLER K, et al. Non-invasive differentiation of kidney stone types using X-ray dark-field radiography[J]. Sci Rep, 2015, 5: 9527.
LIDÉN M. A new method for predicting uric acid composition in urinary stones using routine single-energy CT[J]. Urolithiasis, 2018, 46(4): 325-332.
NESTLER T, NESTLER K, NEISIUS A, et al. Diagnostic accuracy of third-generation dual-source dual-energy CT: a prospective trial and protocol for clinical implementation[J]. World J Urol, 2019, 37(4): 735-741.
GOLDFARB D S. Empiric therapy for kidney stones[J]. Urolithiasis, 2019, 47(1): 107-113.
DAUW C A, YI Y, BIERLEIN M J, et al. Factors associated with preventive pharmacological therapy adherence among patients with kidney stones[J]. Urology, 2016, 93: 45-49.
李梅, 刘付海平, 欧法玲, 等. 知信行模式对泌尿系结石术后饮食依从性及复发率和并发症的影响[J]. 护理实践与研究, 2019, 16(22): 87-89. 郑钰凤, 李晨, 张宏, 等. 中山市小榄地区泌尿系结石患者预防复发知信行的调查研究[J]. 实用临床护理学电子杂志, 2018, 3(38): 15-17. SMALL A C, THOROGOOD S L, SHAH O, et al. Emerging mobile platforms to aid in stone management[J]. Urol Clin North Am, 2019, 46(2): 287-301.
计量
- 文章访问数: 929
- HTML全文浏览量: 229
- PDF下载量: 101
下载:
苏公网安备 32100302010246号
